Atorvastatin + Probucol

The combination of atorvastatin and probucol is a therapeutic approach used primarily for treating atherosclerotic conditions and ischemic stroke. This combination therapy has shown significant synergistic effects in reducing blood lipids, improving antioxidant activity, and providing anti-atherosclerotic benefits beyond what either medication can achieve alone. ## Pharmacological Properties Atorvastatin belongs to the statin class of medications that work by inhibiting HMG-CoA reductase, thereby reducing cholesterol production in the liver. Probucol is an antioxidant and lipid-lowering agent that works through different mechanisms, including facilitating reverse cholesterol transport and providing potent antioxidative effects[1][2]. When combined, these medications demonstrate several beneficial effects: - **Enhanced lipid regulation**: The combination significantly reduces total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels more effectively than atorvastatin alone[1][3]. - **Potent antioxidant activity**: The combination therapy increases paraoxonase-1 (PON1) activity while decreasing oxidized LDL (ox-LDL), providing synergistic antioxidant effects[3]. - **Anti-atherosclerotic effects**: Studies in cholesterol-fed rabbits showed that probucol added to atorvastatin treatment reduced atherosclerotic lesion formation by 61%, compared to just 21% with atorvastatin alone[2]. - **Improved neurological outcomes**: In patients with ischemic stroke, the combination therapy showed better efficacy in improving neurological deficit scores compared to atorvastatin monotherapy[1]. ## Clinical Applications The atorvastatin + probucol combination has been studied for several conditions: 1. **Ischemic stroke**: The combination has shown significant effects in treating ischemic stroke and preventing recurrence, with improvements in neurological deficit scores[1]. 2. **Atherosclerosis**: Animal studies demonstrate potent anti-atherosclerotic effects when the drugs are combined, suggesting benefits for patients with atherosclerotic disorders who have inadequate response to statins alone[2]. 3. **Acute Coronary Syndrome (ACS)**: The combination therapy has shown safety and efficacy in ACS patients, with synergistic effects in lowering cholesterol levels and improving antioxidant activity[3]. 4. **Contrast-induced acute kidney injury**: The combination may help reduce serum uric acid levels during the perioperative period of interventional procedures, potentially improving kidney protection[4]. ## Safety Profile The combination of atorvastatin and probucol appears to be generally well-tolerated. Studies have not reported serious adverse effects on hepatic or renal functions, indications of muscle damage, or severe gastrointestinal reactions[3]. However, probucol is known to potentially cause QT interval prolongation, which should be monitored. The research suggests that probucol may be effective at doses lower than those currently used clinically when combined with atorvastatin, potentially allowing for improved safety profiles while maintaining therapeutic efficacy[2].